Current Liabilities
Deferred Revenue
Moderna Deferred Revenue increased by 3.0% to $102.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 18.4%, from $125.00M to $102.00M. Over 5 years (FY 2020 to FY 2025), Deferred Revenue shows a downward trend with a -52.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ4 2017
Last reportedQ1 2026May 1, 2026
How to read this metric
An increase is generally positive, signaling strong future demand and cash collection, while a decrease indicates the fulfillment of obligations.
Detailed definition
This represents payments received from customers for goods or services that have not yet been delivered or performed. It...
Peer comparison
Common in subscription and long-term contract businesses; highly indicative of future revenue visibility.
Metric ID:
deferred_revenue_currentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.30B | $7.98B | $6.25B | $5.60B | $4.09B | $4.00B | $2.04B | $1.22B | $1.04B | $1.37B | $568.00M | $559.00M | $702.00M | $379.00M | $153.00M | $125.00M | $218.00M | $163.00M | $99.00M | $102.00M |
| QoQ Change | — | +9.2% | -21.6% | -10.5% | -26.9% | -2.2% | -49.1% | -40.2% | -14.7% | +31.9% | -58.6% | -1.6% | +25.6% | -46.0% | -59.6% | -18.3% | +74.4% | -25.2% | -39.3% | +3.0% |
| YoY Change | — | — | — | — | -43.9% | -49.8% | -67.4% | -78.2% | -74.6% | -65.7% | -72.1% | -54.1% | -32.5% | -72.4% | -73.1% | -77.6% | -68.9% | -57.0% | -35.3% | -18.4% |
Range$99.00M – $7.98B
CAGR-59.3%
Avg YoY Growth-58.8%
Median YoY Growth-66.6%
Product Breakdown
| Segment | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
|---|---|---|---|---|---|---|---|---|
| Net product sales | $1.20B | $1.00B | $1.40B | $554.00M | $522.00M | $645.00M | $361.00M | $130.00M |
| Total | $1.22B | $1.04B | $1.37B | $568.00M | $559.00M | $702.00M | $379.00M | $153.00M |
Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Moderna's deferred revenue?
- Moderna (MRNA) reported deferred revenue of $102.00M in Q1 2026.
- How has Moderna's deferred revenue changed year-over-year?
- Moderna's deferred revenue decreased by 18.4% year-over-year, from $125.00M to $102.00M.
- What is the long-term trend for Moderna's deferred revenue?
- Over 5 years (2020 to 2025), Moderna's deferred revenue has grown at a -52.0% compound annual growth rate (CAGR), from $3.87B to $99.00M.
- What does deferred revenue mean?
- Cash received from customers for work that has not yet been completed.